

### **Together We Are Strong**

ISMRD's International Glycoproteinoses Forum

In Minneapolis, MN and From Around the World!



More Information: www.ismrd.org







### **THURSDAY, AUGUST 7TH**

### TOGETHER WE ARE STRONG

ISMRD is delighted to introduce you to its
7th International Glycoproteinoses Family and
Scientific Forum. The theme of our forum is in keeping
with ISMRD's mission of seeking to detect and cure
the Glycoprotein Storage Diseases, and to provide a
global network of support and information, through
partnerships built with medicine, science and industry.
Working together is our GREATEST STRENGTH!

The Forum will combine both in-person and remote presentations as well as webinar access for families around the globe.

ISMRD WELCOMES YOU ALL!

4:00 PM -6:00 PM

REGISTRATION CHECK-IN







### FRIDAY, AUGUST 8TH

7:00 AM - 8:30 AM 8:00 AM - 8:05 AM 8:10 AM - 8:15 AM 8:20 AM - 8:25 AM 8:25 AM - 8:30 AM 8:30 AM - 8:35 AM 8:35 AM - 8:40 AM 8:45 AM - 8:55 AM

#### **BREAKFAST**

- Welcome Carolyn Paisley-Dew, ISMRD President
- Opening of the Forum Marc Patterson, M.D.
- Our Mission Chester B. Whitley, Ph.D., M.D.
- Overview "Think Tank" White Paper & NIH Grant
- The Status of Patient Needs, Treatment, The Future
- Outcome Measures Chester B. Whitley, Ph.D., M.D.
- Patient Voice: Unmet Medical Needs
   Jeanine Jarnes, PharmD, BCOP, BCPS

### ALPHA-MANNOSIDOSIS

- Overview Karolina M Stepien, M.D., Ph.D.
- Treating the Whole Brain in Large Animal Homologue of Alpha-Mannosidosis John H Wolfe, VMD, Ph.D.
- Options of Therapy in Alpha-Mannosidosis
   Robert Šáhó, M.D.
- Patient Voice: The Journey that Changed Everything
   Sarah Forsman, ISMRD Communications Officer
- Long-Term Effects of BMT in Alpha-Mannosidosis
   Julie B Eisengart, Ph.D., LP
- Patient Voice Discussion: Unmet Medical Needs

Coffee Break

9:00 AM - 9:05 AM 9:10 AM - 9:20 AM

9:25 AM - 9:35 AM

9:40 AM - 9:50 AM

9:55 AM - 10:05 AM

10:10 AM - 10:20 AM 10:20 AM - 10:35 AM







10:35 AM - 10:40 AM 10:40 AM - 10:50 AM

10:50 AM - 11:00 AM

11:05 AM - 11:15 AM

11:20 AM - 11:30 AM

11:35 AM - 11:40 AM 11:40 AM - 11:50 AM

11:55 AM - 12:05 PM

12:10 PM - 12:20 PM

12:25 PM - 12:35 PM

12:40 PM - 1:40 PM

### ASPARTYLGLUCOSAMINURIA (AGU)

- Overview Karolina M Stepien, M.D., Ph.D.
- Clinical Manifestations and Long-Term Outcomes in Adults with AGU Karolina M Stepien, M.D., Ph.D.
- Patient Voice: Unmet Medical Needs
   Chester B. Whitley, Ph.D., M.D.
- Outcome Measures of HSCT for AGU
   Troy Lund, Ph.D., M.D.
- Patient Voice Discussion: Unmet Medical Needs

#### **BETA-MANNOSIDOSIS**

- Overview Virginia Kimonis, M.D., M.R.C.P.
- How to Fast-Track Through FDA Approval for ERT & Natural History Study Virginia Kimonis, M.D., M.R.C.P.
- Beta-Mannosidosis Revisited
   Angela Martin Rios M.D., MSC
- Patient Voice: Beta-Mannosidosis Parent and Patient Advocate, The Lost Enzyme Project Laurel Gregier, ISMRD Board Member
- Patient Voice Discussion: Unmet Medical Needs

LUNCH









1:40 PM - 1:45 PM <u>1:45 PM - 1:</u>55 PM

2:00 PM - 2:10 PM 2:15 PM - 2:25 PM

2:30 PM - 2:40 PM

2:45 PM - 2:55 PM 3:00 PM - 3:15 PM

3:15 PM - 3:20 PM 3:20 PM - 3:25 PM 3:30 PM - 3:35 PM

3:40 PM - 3:45 PM 3:45 PM - 3:55 PM 4:00 PM - 4:10 PM

4:15 PM - 4:30 PM 4:30 PM - 5:30 PM 5:30 PM

#### **FUCOSIDOSIS**

- Overview Karolina M Stepien, M.D., Ph.D.
- Long-Term Outcomes of Fucosidosis in Adults
   Karolina M Stepien, M.D., Ph.D.
- HSCT for Fucosidosis Troy Lund, Ph.D., M.D.
- Patient Voice: Fucosidosis Parent and Patient Advocate
   Carolyn Paisley-Dew, ISMRD President
- Evaluation of the Effects of JR-471
   Mathias Schmidt, PD, Ph.D.
- Patient Voice Discussion: Unmet Medical Needs

  BREAK

#### SCHINDLER DISEASE

- Overview R.J. Desnick, M.D., Ph.D.
- Current Approaches to Treatment R.J. Desnick, M.D., Ph.D.
- Patient Voice: Unmet Medical Needs
   Chester B. Whitley, Ph.D., M.D.
- Outcome Measures R.J. Desnick, M.D., Ph.D.
- Patient Voice Discussion: Unmet Medical Needs
- End of Day Recap
   Chester B. Whitley, Ph.D., M.D. & Marc Patterson, M.D.
- GROUP PHOTO
- POSTER SESSION

**CLOSE OF DAY 1** 









#### **POSTERS**

4:30 PM - 5:30 PM

- AAV-based gene therapy as a treatment strategy in a Fucosidosis mouse model Hannah Bäumges, MS
- A novel homozygous variant in MAN2B1 causing Alpha-Mannosidosis

  Gabriela Ponte de Mattos
- Outcome of haemopoietic stem cell transplantation in
   21 patients with Alpha-Mannosidosis Robert Šáhó, M.D.
- Evaluation of the effects of JR-471, a transferrin receptor-targeted alpha-L-fucosidase, on the disease phenotypes of a murine model of Fucosidosis
   Mathias Schmidt, PD, Ph.D.
- Real world reflections of the patient odyssey in Alpha-Mannosidosis:
   Insights and Challenges in diagnosis Sonia Sgrò
- The diagnostic odyssey of a biochemically confirmed case of ML II: a casereport of the first western patient with multiple dysplasia type Ain-Naz Professor Fernanda Sperb Ludwig
- Hormonal dysfunction as a long-term complication of Glycoproteinoses
   Karolina M Stepien, M.D., Ph.D.
- Quality of life and burden of caregivers of patients with Alpha-Mannosidosis: Results from an international survey Karolina M Stepien, M.D., Ph.D.
- Secondary mitochondrial dysfunction in Glycoproteinoses:
   Alpha-Mannosidosis and Fucosidosis Karolina M Stepien, M.D., Ph.D.
- Improving blood-brain barrier penetration in Hurler syndrome using an IDUA-ApoE fusion enzyme delivered via the PS Gene Editing System

  Chester B. Whitley, Ph.D., M.D.
- Penetrating the blood-brain barrier: Utilizing the PS gene editing system to encode a novel fusion β-galactosidase for the treatment of GM1-gangliosidosis Chester B. Whitley, Ph.D., M.D.





### **SATURDAY, AUGUST 9TH**

7:00 AM - 8:30 AM 8:00 AM - 8:05 AM

8:10 AM - 8:15 AM 8:15 AM - 8:25 AM

8:30 AM - 8:40 AM

8:45 AM - 8:55 AM 9:00 AM - 9:10 AM

9:15 AM - 9:20 AM 9:20 AM - 9:30 AM

9:30 AM - 9:40 AM

9:45 AM - 9:55 AM 10:00 AM - 10:10 AM 10:15 AM - 10:30 AM

### **BREAKFAST**

• Recap Our Mission Marc Patterson, M.D.

### **GALACTOSIALIDOSIS**

- Overview Leigh Fremuth, Ph.D.
- The Journey to Therapy in Galactosialidosis
   Leigh Fremuth, Ph.D.
- Patient Voice: Galactosialidosis Patient Advocate,
   Galactosialidosis Network
   Çağdaş Canbolat, ISMRD Board Member
- Outcome Measures Marc Patterson, M.D.
- Patient Voice Discussion: Unmet Medical Needs

### **SIALIDOSIS**

- Overview Leigh Fremuth, Ph.D.
- Understanding Mechanisms of Pathogenesis to Treat Sialidosis Leigh Fremuth, Ph.D.
- Patient Voice: The Path to Gene Therapy
   Sialidosis Patient Advocate Dan Peach, Cure Mucolipidosis
- Outcome Measures Marc Patterson, M.D.
- Patient Voice Discussion: Unmet Medical Needs

### Coffee Break







### SATURDAY, AUGUST 9TH continued

10:30 AM - 10:35 AM

10:35 AM - 10:45 AM 10:50 AM - 11:00 AM

11:05 AM - 11:15 AM 11:20 AM - 11:30 AM 11:35 AM - 11:50 AM

11:55 AM - 12:00 PM 12:05 PM - 12:15 PM 12:20 PM - 12:30 PM

12:35 PM - 12:45 PM 12:50 PM - 1:00 PM 1:05 PM - 1:20 PM

1:25 PM - 1:30 PM

#### **MUCOLIPIDOSIS II**

- Overview of GNPTAB-related (ML) disorders Richard Steet, Ph.D.
- Mechanisms of Drug Resistance in ML Richard Steet, Ph.D.
- Patient Voice: Patient Survey Mucolipidosis Diseases
   Jackie James, Cure Mucolipidosis President
- Outcome Measures Patricia Dickson, M.D.
- Patient Voice Discussion: Unmet Medical Needs

#### SNACK BREAK

### MUCOLIPIDOSIS II/III alpha/beta

- Overview Patricia Dickson, M.D.
- Preclinical research in ML II/III a/b Patricia Dickson, M.D.
- Patient Voice: Mucolipidosis Patient Advocate
   Jackie James, Cure Mucolipidosis President
- Outcome Measures Patricia Dickson, M.D.
- Patient Voice Discussion: Unmet Medical Needs
- Recap and Next Steps Our Mission: The ISMRD Project Chester B. Whitley, Ph.D., M.D. & Marc Patterson, M.D.
- Thank You from ISMRD Danielle Forsman,
   Alpha-Mannosidosis Parent, ISMRD Treasurer

**CLOSE OF FORUM** 

